These effects are mediated through ROS reduction and activation of the PI3K/AKT/mTOR/Snail pathway, highlighting GPX2 as a potential diagnostic biomarker and therapeutic target in NSCLC [59]. This evidence concerns the gene MTOR and non-small cell lung carcinoma.